These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 10332486

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C.
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma.
    Dall'Oglio MF, Ribeiro-Filho LA, Antunes AA, Crippa A, Nesrallah L, Gonçalves PD, Leite KR, Srougi M.
    J Urol; 2007 Aug; 178(2):425-8; discussion 428. PubMed ID: 17561167
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
    Vartanian AA, Stepanova EV, Gutorov SL, Solomko ESh, Grigorieva IN, Sokolova IN, Baryshnikov AY, Lichinitser MR.
    Can J Urol; 2009 Aug; 16(4):4726-32. PubMed ID: 19671223
    [Abstract] [Full Text] [Related]

  • 30. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome.
    Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M.
    J Urol; 2002 Aug; 168(2):762-5. PubMed ID: 12131365
    [Abstract] [Full Text] [Related]

  • 31. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS.
    Cancer; 2005 Jun 15; 103(12):2517-25. PubMed ID: 15880379
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Prognostic value of microscopic venous invasion in renal cell carcinoma: long-term follow-up.
    Lang H, Lindner V, Letourneux H, Martin M, Saussine C, Jacqmin D.
    Eur Urol; 2004 Sep 15; 46(3):331-5. PubMed ID: 15306103
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.
    Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B.
    Eur Urol; 2006 Dec 15; 50(6):1272-7. PubMed ID: 16814458
    [Abstract] [Full Text] [Related]

  • 37. Expression of bone morphogenetic proteins, the subfamily of the transforming growth factor-beta superfamily, in renal cell carcinoma.
    Kwak C, Park YH, Kim IY, Moon KC, Ku JH.
    J Urol; 2007 Sep 15; 178(3 Pt 1):1062-7. PubMed ID: 17644140
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.